Inaqovi is a cancer medicine used in adults to treat newly diagnosed acute myeloid leukaemia (AML), a type of cancer affecting the white blood cells. It is used in patients who are not eligible for standard induction chemotherapy (initial treatment with cancer medicines). Inaqovi contains two active substances, decitabine and cedazuridine.
Therapeutic Indication
### Therapeutic indication Inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy.
Therapeutic Area (MeSH)
N/AATC Code
L01BC58
ATC Item
decitabine, combinations
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
N/AINN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| cedazuridine | N/A | Cedazuridine |
| decitabine | N/A | 地西他滨 |
EMA Name
Inaqovi
Medicine Name
Inaqovi
Aliases
N/ANo risk management plan link.
